Retrospective Analysis of Treatment Situation in Gansu Province: 105 Cases of Glioma

Objective To learn about the current treatments on glioma patients in Gansu Province, and to compare the differences between current treatments and China Clinical Practice Guidelines for the diagnosis and treatment of central nervous system glioma. Methods We collected the clinical data of 105 glioma patients treated in the Lanzhou University Second Hospital and Gansu Province Tumor Hospital from Jan. 2011 to Jan. 2014. Age, gender, tumor location, surgery and chemoradiotherapy were fully analyzed. Results Totally 105 glioma patients were included, 68 males and 37 females. Main treatment methods on all glioma patients included surgery and chemoradiotherapy. The chemotherapy regimens were VP and TMZ. 59.0% (62/105) of glioma patients received chemotherapy. Within 69 patients with high-grade glioma, 72.6% (45/69) of patients received chemotherapy, among which 40.0%(18/45) received TMZ regimen and 60.0%(27/45) received VP regimen(χ2=2.583, P<0.05). Whereas, China Clinical Practice Guidelines for glioma strongly recommends postoperative adjuvant chemoradiotherapy. Conclusion Comparing current treatments in Gansu Province with China Clinical Practice Guidelines for glioma, there are obvious difference in treatment aspects, especially in chemotherapy. Under the guide of glioma guidelines, clinical doctors should establish a feasible individualized comprehensive treatment, which is “individualized treatment, standardization implementation”.